Dose Escalation for Persistent Tiredness on Sunosi 75mg
Increase Sunosi to 150 mg once daily upon awakening, as the FDA-approved dosing allows doubling the dose at intervals of at least 3 days based on efficacy and tolerability. 1
Immediate Next Steps
- Verify the diagnosis by confirming the underlying condition (narcolepsy vs. OSA) and ensure adequate treatment duration, as solriamfetol typically shows effects within 2 weeks of initiation 2, 3
- For OSA patients specifically, confirm that CPAP or other airway obstruction treatment has been optimized and used consistently for at least one month before adjusting solriamfetol, as the drug is not a substitute for treating the underlying airway obstruction 1
- Assess blood pressure before dose escalation, as solriamfetol increases systolic and diastolic blood pressure in a dose-dependent manner, and hypertension must be controlled prior to increasing the dose 1
Dose Titration Protocol
- Double the current dose from 75 mg to 150 mg once daily upon awakening, waiting at least 3 days between dose adjustments 1
- The maximum recommended dose is 150 mg daily for both narcolepsy and OSA, as dosages above 150 mg do not provide increased effectiveness sufficient to outweigh dose-related adverse reactions 1
- Real-world data shows that most patients (56%) stabilize on 75 mg/day, while 40% require 150 mg/day, with most patients adjusting dosages only once over a median of 14 days 4
Monitoring Requirements
- Use the Epworth Sleepiness Scale (ESS) at each visit to objectively track treatment response, as this is the recommended tool for monitoring subjective sleepiness 5, 6
- Monitor blood pressure and heart rate at each follow-up visit, particularly in patients with cardiovascular risk factors, pre-existing hypertension, diabetes, hyperlipidemia, or high BMI 1
- Watch for adverse effects including headache (9%), decreased appetite (6%), insomnia (6%), nausea, dizziness, and palpitations, which typically occur within 2 weeks of treatment initiation and mostly resolve within 2 weeks 2, 3
- Schedule more frequent follow-up when adjusting doses to monitor for hypertension, palpitations, arrhythmias, irritability, or behavioral manifestations 5
Expected Outcomes
- Real-world studies demonstrate mean ESS scores improve from 17.6 at initiation to 13.6 at follow-up, with >90% of patients perceiving slight to strong improvements in EDS 3
- Effect duration is typically 6 to <10 hours in 62% of patients, with 72% reporting no change in perceived nighttime sleep quality 3
- Most patients (96%) remain stable on solriamfetol at follow-up in real-world practice 4
Alternative Options if 150mg Remains Inadequate
- Consider adding modafinil 100-200 mg once upon awakening if solriamfetol alone at maximum dose proves insufficient, as modafinil is strongly recommended as first-line therapy and can be used in combination 5, 6
- Methylphenidate or dextroamphetamine 2.5-5 mg with breakfast (and potentially at lunch if needed, no later than 2:00 PM) represent second-line stimulant options 5, 7, 6
- For narcolepsy patients with cataplexy, sodium oxybate should be considered as it treats both excessive daytime sleepiness and cataplexy comprehensively 5, 6
Critical Pitfalls to Avoid
- Do not exceed 150 mg daily of solriamfetol, as higher doses do not provide additional benefit and increase adverse reactions 1
- Do not administer within 9 hours of planned bedtime, as late-day dosing can interfere with nighttime sleep 1
- Do not use with MAO inhibitors or within 14 days of discontinuing MAO inhibitors due to risk of hypertensive reaction 1
- Do not assume all sleepiness is medication-responsive without first excluding inadequate sleep opportunity, untreated sleep-disordered breathing, or other contributing medical conditions 5, 6
Renal Function Considerations
- Check renal function if not recently assessed, as dose adjustments are required for moderate to severe renal impairment (maximum 75 mg daily for eGFR 30-59 mL/min/1.73 m², maximum 37.5 mg daily for eGFR 15-29 mL/min/1.73 m²) 1